Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05452928 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Aciclovir Versus Placebo for HSV-2 Meningitis

Study acronym: AMEN
StatusNot Yet Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Jun 1, 2025 to Jun 1, 2026v4
  2. Primary completion date: Jun 1, 2027 to Jun 1, 2028
    • Start date: Jan 1, 2024 to Jun 1, 2025
    • Study completion date: Jun 1, 2028 to Jun 1, 2029
    v3
  3. Start date: Oct 1, 2022 to Jan 1, 2024v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To determine whether active treatment with (val)acyclovir is superior for treatment of viral meningitis compared with placebo assessed by numbers meeting a primary, objective endpoint at 7 days after randomisation
Trial Details
NCT Number NCT05452928
Lead Sponsor Jacob Bodilsen
Conditions
(from sponsor)		 Herpes Simplex 2, Meningitis, Viral
Related terms Meningitis, Meningitis, Aseptic, Meningitis, Viral
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov